The impact of imperfect screening tools on measuring the prevalence of epilepsy and headaches in Burkina Faso

• Published in: PLoS neglected tropical diseases 2019-01, Vol.13 (1), p.e0007109-e0007109
• Main Authors: Sahlu, Ida, Bauer, Cici, Ganaba, Rasmané, Preux, Pierre-Marie, Cowan, Linda D, Dorny, Pierre, Millogo, Athanase, Carabin, Hélène
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Bayesian analysis; Bias; Burkina Faso - epidemiology; Child; Child, Preschool; Communities; Cross-Sectional Studies; Cysticercosis; Developing countries; Development and progression; Disease; Disorders; Epidemiology; Epilepsy; Epilepsy - diagnosis; Epilepsy - epidemiology; Estimates; Exact solutions; Female; Headache; Headache Disorders - diagnosis; Headache Disorders - epidemiology; Headaches; Health sciences; Health screening; Humans; Industrialized nations; LDCs; Life Sciences; Male; Mass Screening - methods; Mathematical models; Medical research; Medicine and Health Sciences; Middle Aged; Neurocysticercosis - complications; Neurologic examination; Neurological diseases; Neurological disorders; People and Places; Population; Prevalence; Probability theory; Public health; Questionnaires; Randomized Controlled Trials as Topic; Research and Analysis Methods; Risk factors; Rural areas; Santé publique et épidémiologie; Sensitivity; Sensitivity and Specificity; Specificity; Studies; Surveys and Questionnaires - standards; Systematic review; Tropical climate; Tropical diseases; Validity; Veterinary medicine; Young Adult
• ISSN: 1935-2735; 1935-2727; 1935-2735
• DOI: 10.1371/journal.pntd.0007109

Epilepsy and progressively worsening severe chronic headaches (WSCH) are the two most common clinical manifestations of neurocysticercosis, a form of cysticercosis. Most community-based studies in sub-Saharan Africa (SSA) use a two-step approach (questionnaire and confirmation) to estimate the prevalence of these neurological disorders and neurocysticercosis. Few validate the questionnaire in the field or account for the imperfect nature of the screening questionnaire and the fact that only those who screen positive have the opportunity to be confirmed. This study aims to obtain community-based validity estimates of a screening questionnaire, and to assess the impact of verification bias and misclassification error on prevalence estimates of epilepsy and WSCH. Baseline screening questionnaire followed by neurological examination data from a cluster randomized controlled trial collected between February 2011 and January 2012 were used. Bayesian latent-class models were applied to obtain verification bias adjusted validity estimates for the screening questionnaire. These models were also used to compare the adjusted prevalence estimates of epilepsy and WSCH to those directly obtained from the data (i.e. unadjusted prevalence estimates). Different priors were used and their corresponding posterior inference was compared for both WSCH and epilepsy. Screening data were available for 4768 individuals. For epilepsy, posterior estimates for the sensitivity varied with the priors used but remained robust for the specificity, with the highest estimates at 66.1% (95%BCI: 56.4%;75.3%) for sensitivity and 88.9% (88.0%;89.8%) for specificity. For WSCH, the sensitivity and specificity estimates remained robust, with the highest at 59.6% (49.7%;69.1%) and 88.6% (87.6%;89.6%), respectively. The unadjusted prevalence estimates were consistently lower than the adjusted prevalence estimates for both epilepsy and WSCH. This study demonstrates that in some settings, the prevalence of epilepsy and WSCH can be considerably underestimated when using the two-step approach. We provide an analytic solution to obtain more valid prevalence estimates of these neurological disorders, although more community-based validity studies are needed to reduce the uncertainty of the estimates. Valid estimates of these two neurological disorders are essential to obtain accurate burden values for neglected tropical diseases such as neurocysticercosis that manifest as epilepsy or WSCH. ClinicalTrials